Unknown

Dataset Information

0

The endocannabinoid system as a target for novel anxiolytic drugs.


ABSTRACT: The endocannabinoid (eCB) system has attracted attention for its role in various behavioral and brain functions, and as a therapeutic target in neuropsychiatric disease states, including anxiety disorders and other conditions resulting from dysfunctional responses to stress. In this mini-review, we highlight components of the eCB system that offer potential 'druggable' targets for new anxiolytic medications, emphasizing some of the less well-discussed options. We discuss how selectively amplifying eCBs recruitment by interfering with eCB-degradation, via fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), has been linked to reductions in anxiety-like behaviors in rodents and variation in human anxiety symptoms. We also discuss a non-canonical route to regulate eCB degradation that involves interfering with cyclooxygenase-2 (COX-2). Next, we discuss approaches to targeting eCB receptor-signaling in ways that do not involve the cannabinoid receptor subtype 1 (CB1R); by targeting the CB2R subtype and the transient receptor potential vanilloid type 1 (TRPV1). Finally, we review evidence that cannabidiol (CBD), while representing a less specific pharmacological approach, may be another way to modulate eCBs and interacting neurotransmitter systems to alleviate anxiety. Taken together, these various approaches provide a range of plausible paths to developing novel compounds that could prove useful for treating trauma-related and anxiety disorders.

SUBMITTER: Patel S 

PROVIDER: S-EPMC5407316 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

The endocannabinoid system as a target for novel anxiolytic drugs.

Patel Sachin S   Hill Mathew N MN   Cheer Joseph F JF   Wotjak Carsten T CT   Holmes Andrew A  

Neuroscience and biobehavioral reviews 20170501 Pt A


The endocannabinoid (eCB) system has attracted attention for its role in various behavioral and brain functions, and as a therapeutic target in neuropsychiatric disease states, including anxiety disorders and other conditions resulting from dysfunctional responses to stress. In this mini-review, we highlight components of the eCB system that offer potential 'druggable' targets for new anxiolytic medications, emphasizing some of the less well-discussed options. We discuss how selectively amplifyi  ...[more]

Similar Datasets

| S-EPMC7037210 | biostudies-literature
| S-EPMC5552560 | biostudies-other
| S-EPMC7502221 | biostudies-literature
| S-EPMC6459931 | biostudies-literature
| S-EPMC3681125 | biostudies-other
| S-EPMC3780360 | biostudies-literature
| 10825 | ecrin-mdr-crc
| S-EPMC8011453 | biostudies-literature
| S-EPMC7037698 | biostudies-literature
| S-EPMC10081722 | biostudies-literature